FDA Issues 30 Warning Letters to Telehealth Firms Over Misleading Compounded GLP-1 Marketing

The FDA has announced the issuance of 30 warning letters to telehealth companies, targeting firms making false or misleading claims regarding compounded GLP-1 products, such as semaglutide and tirzepatide, offered on their digital platforms.¹

The announcement marks the second major wave of warning letters sent to telehealth firms since the agency initiated a broader "crackdown" on misleading direct-to-consumer (DTC) advertising in September 2025.² Over the last six months, the FDA has dispatched thousands of letters to pharmaceutical and telehealth companies, a volume that exceeds the total sent over the preceding decade.¹

FDA Commissioner Marty Makary, MD, MPH, characterized the agency's current posture as a fundamental shift in regulatory strategy. “It's a new era. We are paying close attention to misleading claims being made by telehealth and pharma companies across all media platforms—and taking swift action,” Makary said.¹ He further emphasized that while compounded drugs serve a role in addressing shortages, they must not be used to bypass federal standards. “Compounded drugs can be important for overcoming shortages or meeting unique patient needs—but compounders should not try to compound drugs in a way that circumvents FDA's approval process."¹

What Specific Violations and Commercial Risks Has the FDA Identified?

For stakeholders in the pharma commercialization space, the specific violations cited in the letters highlight critical boundaries for digital marketing. The primary infractions included:

• Claims of "Sameness": Marketing materials that implied compounded versions were identical to FDA-approved products.
• Obscured Sourcing: Advertising drug products branded with the telehealth firm’s own name or trademark without clarifying that the firm is not the actual compounder.¹

The FDA reiterated that compounded drugs are not FDA-approved, meaning the agency does not review their safety, effectiveness, or quality prior to marketing. Furthermore, the agency clarified that compounded drugs are not the same as generic drugs, which are FDA-approved.

What Motivated the FDA’s Shift Toward Proactive Regulatory Oversight?

The current regulatory environment is influenced by a September 2025 executive order aimed at enhancing transparency in DTC prescription drug advertising. This order spurred the FDA to transition from its traditional reactive, complaint-driven oversight to a more proactive monitoring system for all pharmaceutical advertising.²

Research indicates that DTC advertising significantly impacts patient behavior, increasing overall prescription requests and the likelihood of a clinician fulfilling those requests, even when prescribers question the clinical appropriateness of the medication.² By moving to proactive monitorization, the FDA aims to ensure that all promotional content represents a “fair balance” of risks and benefits, as required by the Federal Food, Drug, and Cosmetic Act.

Beyond marketing claims, the news underscores the agency's commitment to protecting the drug supply from poor-quality materials. The FDA remains vigilant regarding fraudulent and counterfeit products, including those containing false label information or non-existent pharmacies.³ To bolster supply chain security, the agency maintains a green list import alert (66-80) to prevent GLP-1 active pharmaceutical ingredients (APIs) with quality concerns from entering the U.S., while still allowing legal importation from compliant manufacturers.³

Today's issuance of 30 warning letters represents a continuation of a significant enforcement trend. By identifying primary violations such as "sameness" claims and obscured sourcing on digital platforms, the FDA is establishing a new standard for transparency and regulatory compliance in the marketing of compounded GLP-1 products.

References

1. FDA. FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s. FDA News Release. March 3, 2026. https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s
2. Jacobus N. FDA Sends Warning Letters to Novo Nordisk, Eli Lilly, and Hims Regarding Misleading Pharmaceutical Advertising. Pharmaceutical Executive. September 17, 2025. https://www.pharmexec.com/view/fda-warning-letters-novo-nordisk-eli-lilly-hims-regarding-misleading-advertising
3. 3.FDA. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Postmarket Drug Safety Information. Current as of February 4, 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss